Carsten Bokemeyer

61.6k total citations · 10 hit papers
957 papers, 36.1k citations indexed

About

Carsten Bokemeyer is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carsten Bokemeyer has authored 957 papers receiving a total of 36.1k indexed citations (citations by other indexed papers that have themselves been cited), including 383 papers in Oncology, 301 papers in Surgery and 244 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carsten Bokemeyer's work include Testicular diseases and treatments (225 papers), Colorectal Cancer Treatments and Studies (113 papers) and Multiple Myeloma Research and Treatments (104 papers). Carsten Bokemeyer is often cited by papers focused on Testicular diseases and treatments (225 papers), Colorectal Cancer Treatments and Studies (113 papers) and Multiple Myeloma Research and Treatments (104 papers). Carsten Bokemeyer collaborates with scholars based in Germany, United States and Switzerland. Carsten Bokemeyer's co-authors include Hans‐Joachim Schmoll, Lothar Kanz, Karin Oechsle, Christian Kollmannsberger, Friedemann Honecker, J.T. Hartmann, Gunter Schuch, J. Beyer, Leendert H. J. Looijenga and Guido Sauter and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Carsten Bokemeyer

904 papers receiving 35.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Carsten Bokemeyer et al. profile →
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

2008 1.2k citations Carsten Bokemeyer, Jorge Aparicio et al. Journal of Clinical Oncology profile →
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

2004 678 citations Carsten Bokemeyer et al. profile →
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 612 citations Carsten Bokemeyer, Gunter Schuch et al. Annals of Oncology profile →
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

2008 568 citations Gunter Schuch, Carsten Bokemeyer et al. Journal of Clinical Oncology profile →
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors.

2003 502 citations Leendert H. J. Looijenga, Hans Stoop et al. profile →
Guidelines on Testicular Cancer: 2015 Update

2015 454 citations Carsten Bokemeyer et al. profile →
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

2012 447 citations Carsten Bokemeyer et al. profile →
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations Carsten Bokemeyer et al. profile →
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 99 citations Carsten Bokemeyer, Gedske Daugaard et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Carsten Bokemeyer

Since Specialization

Citations

This map shows the geographic impact of Carsten Bokemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Bokemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Bokemeyer more than expected).

Fields of papers citing papers by Carsten Bokemeyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Bokemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Bokemeyer. The network helps show where Carsten Bokemeyer may publish in the future.

Co-authorship network of co-authors of Carsten Bokemeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Bokemeyer. A scholar is included among the top collaborators of Carsten Bokemeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Bokemeyer. Carsten Bokemeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Existential distress in advanced cancer: A cohort study 2025 ·General Hospital Psychiatry ·R Philipp, (unknown), Uwe Koch, Karin Oechsle, (unknown), (unknown), (unknown), (unknown), David W. Kissane, Guntram Lock, Christopher Lo, (unknown), Volkmar Müller, Martin Reck, Georgia Schilling, Kornelius Schulze, (unknown), Carsten Bokemeyer, Martin Härter, Sigrun Vehling	1
2	Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria 2024 ·Hämostaseologie ·(unknown), Tobias D. Faizy, Fabian Flottmann, Jens Fiehler, Carsten Bokemeyer, Lennart Well, (unknown), Florian Länger	2
3	611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors 2024 ·Annals of Oncology ·(unknown), Andréas Mackensen, (unknown), Winfried Alsdorf, (unknown), Daniel Heudobler, (unknown), Antonia Busse, Stephan Mielke, Sander Bins, Guy Ungerechts, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, (unknown), Zhong Wei, (unknown), (unknown), Uğur Şahin	7
4	Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement 2024 ·Blood ·(unknown), (unknown), Lisa Leypoldt, (unknown), Xiang Zhou, (unknown), (unknown), (unknown), (unknown), (unknown), Winfried Alsdorf, Max S. Topp, Johannes Duell, (unknown), Johannes M. Waldschmidt, Carsten Bokemeyer, Hermann Einsele, K. Martin Kortüm, Katja Weisel, Leo Rasche	0
5	704P Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study 2024 ·Annals of Oncology ·Christoph Oing, Christoph Seidel, (unknown), A. Tryakin, Ugo De Giorgi, Hege Sagstuen Haugnes, M. Hentrich, Annette Dieing, Stefanie Zschäbitz, Jourik A. Gietema, (unknown), Christian D. Fankhauser, (unknown), Jorge Aparicio, Margaret Ottaviano, Martin Pichler, (unknown), (unknown), (unknown), Carsten Bokemeyer	0
6	Effectiveness of high efficiency particulate (HEPA) air condition combined with the antifungal prophylaxis on incidence, morbidity and mortality of invasive fungal infections in patients with acute myeloid leukemia: a retrospective single-center study 2024 ·Frontiers in Oncology ·(unknown), Eik Vettorazzi, Walter Fiedler, Holger Rohde, Jannik Stemler, (unknown), Carsten Bokemeyer, Cyrus Khandanpour, (unknown), Maxim Kebenko	0
7	High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT 2024 ·ESMO Open ·Simona Secondino, Manuela Badoglio, Gianantonio Rosti, Myriam Labopin, Matthieu Delaye, Carsten Bokemeyer, Christoph Seidel, Edward Kanfer, Elisabetta Metafuni, Jürgen Finke, (unknown), Christos Kosmas, Florent Malard, Alessia Pagani, Jürgen Kuball, Ulrike Koehl, Annalisa Ruggeri, Ugo De Giorgi, Paolo Pedrazzoli	2
8	Increased incidence of immune thrombocytopenia (ITP) in 2021 correlating with the ongoing vaccination campaign against COVID‐19 in a tertiary center – A monocentric analysis 2023 ·British Journal of Haematology ·(unknown), (unknown), Christian Frenzel, Katja Weisel, Carsten Bokemeyer, Christoph Seidel	4
9	New Bioactive β-Resorcylic Acid Derivatives from the Alga-Derived Fungus Penicillium antarcticum KMM 4685 2023 ·Marine Drugs ·(unknown), Alexandr S. Antonov, (unknown), Jessica Hauschild, Olesya I. Zhuravleva, Yuliya V. Khudyakova, (unknown), Roman S. Popov, (unknown), Markus Graefen, Carsten Bokemeyer, Gunhild von Amsberg, Anton N. Yurchenko, Sergey A. Dyshlovoy	9
10	Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors 2023 ·Journal of Clinical Medicine ·(unknown), Christoph Seidel, (unknown), (unknown), Carsten Bokemeyer, Davor Lessel	1
11	Increased frequency of TIGIT ⁺ CD73-CD8 ⁺ T cells with a TOX ⁺ TCF-1low profile in patients with newly diagnosed and relapsed AML 2021 ·OncoImmunology ·Franziska Brauneck, Friedrich Haag, (unknown), (unknown), Eva Tolosa, Anne Rissiek, Gabi Vohwinkel, Jasmin Wellbrock, Carsten Bokemeyer, Julian Schulze zur Wiesch, (unknown), Walter Fiedler	28
12	Late adverse effects and quality of life in survivors of testicular germ cell tumour 2021 ·Nature Reviews Urology ·Michal Chovanec, Jakob Lauritsen, Mikkel Bandak, Christoph Oing, (unknown), Michael Kreiberg, (unknown), Thomas Wagner, Carsten Bokemeyer, Gedske Daugaard	51
13	Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment 2021 ·Cancers ·(unknown), Martin Schönlein, Marc Lütgehetmann, Julian Schulze zur Wiesch, Heiko Becher, Carsten Bokemeyer, Marianne Sinn, Katja Weisel, Lisa Leypoldt	24
14	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies 2019 ·Molecular Cancer Therapeutics ·Joseph Tintelnot, (unknown), Christoph Schultheiß, Friederike Braig, (unknown), (unknown), (unknown), Peter Bannas, Boris Fehse, Kristoffer Riecken, (unknown), Carsten Bokemeyer, Thies Rösner, Thomas Valerius, Matthias Peipp, Friedrich Koch‐Nolte, Mascha Binder	26
15	Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy 2018 ·Cancer Research ·(unknown), (unknown), Mark Wroblewski, Isabel Ben‐Batalla, Ines Miranda Santos, Federico Taverna, (unknown), (unknown), (unknown), Stefan Vinckier, Johanna M. Brandner, Klaus Pantel, Carsten Bokemeyer, Thomas Vogl, Johannes Roth, Peter Carmeliet, Sonja Loges	97
16	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects 2015 ·Clinical Cancer Research ·Jasmin Wellbrock, (unknown), Julian Köhler, Katharina Wagner, Hauke Stamm, Eik Vettorazzi, Gabi Vohwinkel, (unknown), (unknown), (unknown), Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jücker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, Walter Fiedler	86
17	Circulating Tumor Cells in Patients with Testicular Germ Cell Tumors 2014 ·Clinical Cancer Research ·Paulina Nastały, Christian Ruf, (unknown), Natalia Bednarz‐Knoll, (unknown), Refik Kavsur, Hendrik Isbarn, Cord Matthies, Walter Wagner, (unknown), Margit Fisch, Carsten Bokemeyer, Sascha Ahyai, Friedemann Honecker, Sabine Riethdorf, Klaus Pantel	41
18	Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial 2012 ·Journal of Clinical Oncology ·Anja Lorch, (unknown), Andrew Kramar, Christian Kollmannsberger, Jörg T. Hartmann, Carsten Bokemeyer, Oliver Rick, J. Beyer	66
19	Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors 2009 ·Journal of Clinical Oncology ·Friedemann Honecker, Hendrik Wermann, Frank Mayer, Ad Gillis, Hans Stoop, (unknown), Karin Oechsle, Ewout W. Steyerberg, (unknown), Winand N.M. Dinjens, J. Wolter Oosterhuis, Carsten Bokemeyer, Leendert H. J. Looijenga	134
20	Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis 2007 ·Clinical Cancer Research ·Sonja Loges, (unknown), Uta Reichelt, Michaël Bubenheim, Andreas Erbersdobler, Paulus Schurr, Emre F. Yekebas, Gunter Schuch, Jakob R. Izbicki, Klaus Pantel, Carsten Bokemeyer, Walter Fiedler	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact